Actively Recruiting

Phase 2
Phase 3
Age: 0Years - 100Years
All Genders
NCT05948943

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Led by Novartis Pharmaceuticals · Updated on 2026-05-12

232

Participants Needed

56

Research Sites

492 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.

CONDITIONS

Official Title

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Who Can Participate

Age: 0Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent and assent when applicable
  • Willingness to stay at the clinical site and follow study rules
  • Physician-confirmed symptomatic lymphatic malformation not classified under PROS
  • Not a candidate or unwilling to receive non-drug therapies like sclerotherapy, embolization, or surgery until Week 24 of Stage 1 and 2
  • Evidence of a somatic PIK3CA gene mutation before randomization
  • At least one measurable lymphatic malformation lesion confirmed by BIRC before randomization
  • Ability to take study drug in tablet, suspension, granules, or oral suspension form, including via feeding tubes
Not Eligible

You will not qualify if you...

  • Diagnosis of PROS at the time of consent
  • Diagnosis of Central Conducting Lymphatic Anomaly, General Lymphatic Anomaly, Gorham-Stout disease, or Kaposiform lymphangiomatosis
  • History of Stevens-Johnson syndrome, erythema multiforme, or toxic epidermal necrolysis
  • Diagnosis of type I diabetes or uncontrolled type II diabetes at consent
  • Previous treatment with alpelisib or other PI3K inhibitors for more than 2 weeks
  • Other criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 56 locations

1

UCSF Benioff Children s Hospital

Oakland, California, United States, 94609

Actively Recruiting

2

Lucile Packard Childrens Hosp

Palo Alto, California, United States, 94304

Actively Recruiting

3

Childrens National Medical Center

Washington D.C., District of Columbia, United States, 20010-2970

Actively Recruiting

4

Nemours Childrens Clinic

Jacksonville, Florida, United States, 32207

Actively Recruiting

5

Childrens Hosp Boston Dept of Heme

Boston, Massachusetts, United States, 02115

Actively Recruiting

6

WA Uni School Of Med

St Louis, Missouri, United States, 63110

Actively Recruiting

7

Cinn Children Hosp Medical Center

Cincinnati, Ohio, United States, 45206

Actively Recruiting

8

Univ Hospital Of Cleveland

Cleveland, Ohio, United States, 44106

Actively Recruiting

9

Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

Actively Recruiting

10

Nationwide Children s Hospital

Columbus, Ohio, United States, 43205

Actively Recruiting

11

Oregon Health Science University

Portland, Oregon, United States, 97239

Actively Recruiting

12

CHOP Abramson Pediatric Resch Ctr

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

13

Childrens Hosp Pittsburgh UPMC

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

14

Baylor College Of Medicine

Houston, Texas, United States, 77030

Actively Recruiting

15

U of TX Health Science Ct

Houston, Texas, United States, 77030

Actively Recruiting

16

Childrens Hospital and Regional Medical Center

Seattle, Washington, United States, 98105

Actively Recruiting

17

Novartis Investigative Site

CABA, Buenos Aires, Argentina, C1181ACH

Actively Recruiting

18

Novartis Investigative Site

CABA, Buenos Aires, Argentina, C1425BEA

Actively Recruiting

19

Novartis Investigative Site

Capital Federal, Argentina, C1023AAB

Actively Recruiting

20

Novartis Investigative Site

Sydney, New South Wales, Australia, 2010

Actively Recruiting

21

Novartis Investigative Site

Sydney, New South Wales, Australia, 2031

Actively Recruiting

22

Novartis Investigative Site

Brisbane, Queensland, Australia, 4101

Actively Recruiting

23

Novartis Investigative Site

Brussels, Belgium, 1200

Actively Recruiting

24

Novartis Investigative Site

Angers, France, 49933

Actively Recruiting

25

Novartis Investigative Site

Bordeaux, France, 33076

Actively Recruiting

26

Novartis Investigative Site

Bron, France, 69677

Actively Recruiting

27

Novartis Investigative Site

Caen, France, 14033

Actively Recruiting

28

Novartis Investigative Site

Dijon, France, 21000

Actively Recruiting

29

Novartis Investigative Site

Lille, France, 59000

Actively Recruiting

30

Novartis Investigative Site

Marseille, France, 13885

Actively Recruiting

31

Novartis Investigative Site

Montpellier, France, 34295

Actively Recruiting

32

Novartis Investigative Site

Paris, France, 75010

Actively Recruiting

33

Novartis Investigative Site

Paris, France, 75015

Actively Recruiting

34

Novartis Investigative Site

Toulouse, France, 31054

Actively Recruiting

35

Novartis Investigative Site

Tours, France, 37044

Actively Recruiting

36

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106

Actively Recruiting

37

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, Germany, 68305

Withdrawn

38

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany, 50937

Actively Recruiting

39

Novartis Investigative Site

Leipzig, Saxony, Germany, 04103

Actively Recruiting

40

Novartis Investigative Site

Berlin, Germany, 13353

Actively Recruiting

41

Novartis Investigative Site

Bologna, BO, Italy, 40138

Actively Recruiting

42

Novartis Investigative Site

Milan, MI, Italy, 20122

Actively Recruiting

43

Novartis Investigative Site

Roma, RM, Italy, 00165

Actively Recruiting

44

Novartis Investigative Site

Roma, RM, Italy, 00168

Actively Recruiting

45

Novartis Investigative Site

Torino, TO, Italy, 10126

Actively Recruiting

46

Novartis Investigative Site

Naples, Italy, 80122

Actively Recruiting

47

Novartis Investigative Site

Nijmegen, Gelderland, Netherlands, 6500HB

Actively Recruiting

48

Novartis Investigative Site

Rotterdam, South Holland, Netherlands, 3015 GD

Actively Recruiting

49

Novartis Investigative Site

Palma, Balearic Islands, Spain, 07120

Actively Recruiting

50

Novartis Investigative Site

Esplugues, Barcelona, Spain, 08950

Actively Recruiting

51

Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, Spain, 08907

Actively Recruiting

52

Novartis Investigative Site

A Coruña, Spain, 15006

Actively Recruiting

53

Novartis Investigative Site

Barcelona, Spain, 08035

Actively Recruiting

54

Novartis Investigative Site

Madrid, Spain, 28009

Actively Recruiting

55

Novartis Investigative Site

Madrid, Spain, 28046

Actively Recruiting

56

Novartis Investigative Site

Lausanne, Switzerland, 1011

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

9

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | DecenTrialz